Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

PubWeight™: 1.56‹?› | Rank: Top 4%

🔗 View Article (PMC 4083471)

Published in Clin Cancer Res on July 01, 2014

Authors

Yong-Chen Lu1, Xin Yao2, Jessica S Crystal2, Yong F Li2, Mona El-Gamil2, Colin Gross2, Lindy Davis2, Mark E Dudley2, James C Yang2, Yardena Samuels3, Steven A Rosenberg2, Paul F Robbins1

Author Affiliations

1: Authors' Affiliations: Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland; and Yong-Chen.Lu@nih.gov Paul_Robbins@nih.gov.
2: Authors' Affiliations: Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland; and.
3: Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.

Associated clinical trials:

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma | NCT00096382

NCT00335127

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer | NCT03412877

Articles citing this

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med (2016) 3.61

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med (2014) 2.40

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med (2016) 2.36

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. J Clin Oncol (2016) 1.89

Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature (2016) 1.63

Toxicities of Immunotherapy for the Practitioner. J Clin Oncol (2015) 1.50

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest (2015) 1.41

Therapeutic cancer vaccines. J Clin Invest (2015) 1.23

Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature (2016) 1.12

Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med (2016) 1.03

Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol (2015) 0.96

Cancer immunotherapy targeting neoantigens. Semin Immunol (2015) 0.92

Updates in Therapy for Advanced Melanoma. Cancers (Basel) (2016) 0.91

Dendritic Cell-Derived Exosomes may be a Tool for Cancer Immunotherapy by Converting Tumor Cells into Immunogenic Targets. Front Immunol (2015) 0.90

Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech (2015) 0.85

T cell receptor repertoire usage in cancer as a surrogate marker for immune responses. Semin Immunopathol (2017) 0.85

Targeting neoantigens for cancer immunotherapy. Int Immunol (2016) 0.84

Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun (2016) 0.83

High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera. Proteomics (2016) 0.83

Cancer immunoprevention--the next frontier. Cancer Prev Res (Phila) (2014) 0.82

Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. Ann Oncol (2015) 0.82

Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor. Cancer Immunol Res (2016) 0.81

Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. Mol Ther (2016) 0.80

Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PLoS One (2016) 0.79

Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Semin Oncol (2015) 0.79

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. Cancer Immunol Res (2016) 0.79

Current Immunotherapies for Sarcoma: Clinical Trials and Rationale. Sarcoma (2016) 0.79

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol (2016) 0.78

Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges. Semin Oncol (2015) 0.77

Optimizing T-cell receptor gene therapy for hematologic malignancies. Blood (2016) 0.77

Landscape of Tumor Antigens in T Cell Immunotherapy. J Immunol (2015) 0.77

CCR 20th Anniversary Commentary: Autologous T Cells-The Ultimate Personalized Drug for the Immunotherapy of Human Cancer. Clin Cancer Res (2015) 0.76

Current tools for predicting cancer-specific T cell immunity. Oncoimmunology (2016) 0.76

Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget (2016) 0.75

Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets. Hum Vaccin Immunother (2016) 0.75

CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes. Oncoimmunology (2017) 0.75

The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. Int J Mol Sci (2017) 0.75

Temporally Programmed CD8α(+) DC Activation Enhances Combination Cancer Immunotherapy. Cell Rep (2016) 0.75

Tumor-infiltrating lymphocytes (TILs) from patients with glioma. Oncoimmunology (2016) 0.75

'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol (2017) 0.75

Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. Oral Oncol (2016) 0.75

Socializing Individualized T-Cell Cancer Immunotherapy. Mol Ther (2016) 0.75

Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer. Cancer Immunol Immunother (2016) 0.75

The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy. Front Immunol (2017) 0.75

Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncoimmunology (2017) 0.75

Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas. Environ Mol Mutagen (2017) 0.75

Articles cited by this

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77

Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75

SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans. Science (2005) 12.02

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76

Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (1992) 7.04

The DNA replication fork in eukaryotic cells. Annu Rev Biochem (1998) 6.66

Kin I kinesins are microtubule-destabilizing enzymes. Cell (1999) 6.07

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59

Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity (1997) 5.44

Aurora B regulates MCAK at the mitotic centromere. Dev Cell (2004) 4.94

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80

Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45

A standardized kinesin nomenclature. J Cell Biol (2004) 4.43

Eukaryotic DNA polymerases. Annu Rev Biochem (1991) 3.92

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature (2012) 3.83

NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics (2008) 3.59

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29

Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity (2003) 3.14

Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01

Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature (2004) 2.84

The B subunit of the DNA polymerase alpha-primase complex in Saccharomyces cerevisiae executes an essential function at the initial stage of DNA replication. Mol Cell Biol (1994) 2.75

Depolymerizing kinesins Kip3 and MCAK shape cellular microtubule architecture by differential control of catastrophe. Cell (2011) 2.31

The kinesin-13 proteins Kif2a, Kif2b, and Kif2c/MCAK have distinct roles during mitosis in human cells. Mol Biol Cell (2007) 2.19

Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med (2012) 2.04

Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol (2013) 1.50

High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40

An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc Natl Acad Sci U S A (2011) 1.03

A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days. Nat Med (2013) 0.93

A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine (2008) 0.87

Kinesins lead aging microtubules to catastrophe. Cell (2011) 0.79